Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04394247 · ClinicalTrials.gov registry record
Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 242
- Enrollment target
NCT04394247 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 242 participants.
The verdict
NCT04394247 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 242 participants
- Enrollment target
Study Summary
The study is designed to describe patient characteristics, treatment patterns, and clinical effectiveness outcomes in patients diagnosed with HR+/HER2- A/MBC who received palbociclib combination therapy with AI as first-line treatment in the US community oncology setting.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2020-06-30 |
| Est. Completion | 2020-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04394247
The ClinicalTrials.gov registry entry for NCT04394247 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04394247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04394247 about?
NCT04394247 is a clinical study titled "Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy". The study is designed to describe patient characteristics, treatment patterns, and clinical effectiveness outcomes in patients diagnosed with HR+/HER2- A/MBC who received palbociclib combination therapy with AI as first-line treatment in the US community oncology setting.
What is the current status of trial NCT04394247?
This trial is currently completed. The enrollment target is 242 participants. The study started on 2020-06-30. Estimated completion is 2020-12-31.
Who is sponsoring clinical trial NCT04394247?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.